153 related articles for article (PubMed ID: 23079204)
21. Thymosin beta 10 correlates with lymph node metastases of papillary thyroid carcinoma.
Zhang XJ; Su YR; Liu D; Xu DB; Zeng MS; Chen WK
J Surg Res; 2014 Dec; 192(2):487-93. PubMed ID: 24974154
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
[TBL] [Abstract][Full Text] [Related]
23. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.
Rossi ED; Martini M; Capodimonti S; Lombardi CP; Pontecorvi A; Vellone VG; Zannoni GF; Larocca LM; Fadda G
Cancer Cytopathol; 2013 Jun; 121(6):291-7. PubMed ID: 23192956
[TBL] [Abstract][Full Text] [Related]
24. Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma.
Wobker SE; Kim LT; Hackman TG; Dodd LG
Cancer Cytopathol; 2015 Sep; 123(9):531-9. PubMed ID: 26080065
[TBL] [Abstract][Full Text] [Related]
25. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
26. The Wnt/β-catenin pathway drives increased cyclin D1 levels in lymph node metastasis in papillary thyroid cancer.
Zhang J; Gill AJ; Issacs JD; Atmore B; Johns A; Delbridge LW; Lai R; McMullen TP
Hum Pathol; 2012 Jul; 43(7):1044-50. PubMed ID: 22204713
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer.
Wu MH; Shen WT; Gosnell J; Duh QY
Head Neck; 2015 Sep; 37(9):1336-43. PubMed ID: 24821456
[TBL] [Abstract][Full Text] [Related]
28. The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?
Walczyk A; Kowalska A; Kowalik A; Sygut J; Wypiórkiewicz E; Chodurska R; Pięciak L; Góźdź S
Clin Endocrinol (Oxf); 2014 Jun; 80(6):899-904. PubMed ID: 24354346
[TBL] [Abstract][Full Text] [Related]
29. Lateral lymph node metastasis in papillary thyroid carcinoma: results of therapeutic lymph node dissection.
Chung YS; Kim JY; Bae JS; Song BJ; Kim JS; Jeon HM; Jeong SS; Kim EK; Park WC
Thyroid; 2009 Mar; 19(3):241-6. PubMed ID: 19265495
[TBL] [Abstract][Full Text] [Related]
30. Cribriform-morular variant of papillary thyroid carcinoma in an 8-year-old girl: a case report with immunohistochemical and molecular testing.
Rossi ED; Revelli L; Martini M; Taddei A; Pintus C; Panunzi C; Fadda G
Int J Surg Pathol; 2012 Dec; 20(6):629-32. PubMed ID: 22494995
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma.
Koperek O; Kornauth C; Capper D; Berghoff AS; Asari R; Niederle B; von Deimling A; Birner P; Preusser M
Am J Surg Pathol; 2012 Jun; 36(6):844-50. PubMed ID: 22592144
[TBL] [Abstract][Full Text] [Related]
32. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.
Kim BH; Kim IJ; Lee BJ; Lee JC; Kim IS; Kim SJ; Kim WJ; Jeon YK; Kim SS; Kim YK
Yonsei Med J; 2015 May; 56(3):634-40. PubMed ID: 25837167
[TBL] [Abstract][Full Text] [Related]
33. BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases.
Fakhruddin N; Jabbour M; Novy M; Tamim H; Bahmad H; Farhat F; Zaatari G; Aridi T; Kriegshauser G; Oberkanins C; Mahfouz R
Sci Rep; 2017 Jul; 7(1):4666. PubMed ID: 28680105
[TBL] [Abstract][Full Text] [Related]
34. High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes.
Vasko V; Hu S; Wu G; Xing JC; Larin A; Savchenko V; Trink B; Xing M
J Clin Endocrinol Metab; 2005 Sep; 90(9):5265-9. PubMed ID: 15998781
[TBL] [Abstract][Full Text] [Related]
35. Cytomorphological factors and BRAF mutation predicting risk of lymph node metastasis in preoperative liquid-based fine needle aspirations of papillary thyroid carcinoma.
Chung SY; Lee JS; Lee H; Park SH; Kim SJ; Ryu HS
Acta Cytol; 2013; 57(3):252-8. PubMed ID: 23636013
[TBL] [Abstract][Full Text] [Related]
36. [The clinical significance of Delphian lymph node metastasis in papillary thyroid cancer].
Zheng GB; Hao SL; Liu XC; Ning JY; Wu GC; Wang D; Li BY; Jiang LX; Song XC; Zheng HT
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Nov; 51(11):842-845. PubMed ID: 27938611
[No Abstract] [Full Text] [Related]
37. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
[TBL] [Abstract][Full Text] [Related]
38. Papillary microcarcinomas of the thyroid with preoperatively detectable lymph node metastasis show significantly higher aggressive characteristics on immunohistochemical examination.
Ito Y; Uruno T; Takamura Y; Miya A; Kobayashi K; Matsuzuka F; Kuma K; Miyauchi A
Oncology; 2005; 68(2-3):87-96. PubMed ID: 15886500
[TBL] [Abstract][Full Text] [Related]
39. Platelet-derived growth factor receptor-α promotes lymphatic metastases in papillary thyroid cancer.
Zhang J; Wang P; Dykstra M; Gelebart P; Williams D; Ingham R; Adewuyi EE; Lai R; McMullen T
J Pathol; 2012 Oct; 228(2):241-50. PubMed ID: 22744707
[TBL] [Abstract][Full Text] [Related]
40. Molecular analysis of multifocal papillary thyroid carcinoma.
Lin X; Finkelstein SD; Zhu B; Silverman JF
J Mol Endocrinol; 2008 Oct; 41(4):195-203. PubMed ID: 18628356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
